Login to Your Account

Threshold's Oncology Products Emerge Through $41M Series B

By Aaron Lorenzo

Tuesday, January 13, 2004
Stepping into the biotech spotlight, cancer drug developer Threshold Pharmaceuticals Inc. raised $41 million in a second round of financing that attracted new and existing investors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription